Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Clinical Trial ID NCT01804829

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01804829

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013 1.21
2 A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 2005 1.13
Next 100